传染科

订阅

MedSci主页 / 所有栏目 / 传染科

Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答

2021-08-26 国际文传 网络

临床试验新冠肺炎患者澳大利亚临床阶段药物开发公司
关注

继I期临床取得阳性结果后，临床试验向全球扩展

澳大利亚临床阶段药物开发公司Noxopharm (ASX:NOX)已发布其NOXCOVID I期临床试验的初步头条数据，该试验旨在研究TBK1（TANK结合激酶1）抑制剂idronoxil (Veyonda®)是否适合作为一种抗炎药用于中度新冠肺炎疾病患者。基于初步的阳性结果，Noxopharm已开始讨论将Veyonda加入一项全球临床试验，该试验旨在确定新冠肺炎疾病的有效抗炎治疗药物。

阻断型TBK1有两大重要意义：(i)能阻断对RNA病毒（例如冠状病毒和流感病毒）的功能失调的免疫应答；(ii)有望避免标准抗炎药（例如泼尼松和地塞米松）的不良免疫抑制效应，这些效应可能延缓病毒清除，增加继发感染的风险。

Noxopharm首席执行官兼董事总经理Graham Kelly表示：“NOXCOVID I期临床试验结果非常鼓舞人心，Veyonda在其中发挥了重要作用，因为很大比例的患者正在经历炎症加剧。该试验中未见重大安全问题，38例伴中度呼吸系统疾病的住院患者中有37例康复。”

莫纳什大学和哈德逊研究所儿科免疫学教授、莫纳什儿童医院儿科医生Marcel Nold, M.D.表示：“根据目前已知的情况，Veyonda的特性使其有望填补我们新冠肺炎治疗药物阵容中的空白。患者能自行服药，从而实现居家用药。其作用机制能治疗中度新冠肺炎患者，更重要的是，Veyonda还可有效抗击许多其他病毒。Veyonda为Noxopharm带来了一个令人激动的、近在咫尺的机会。”

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎，疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2022-01-13 医生2402

    #I期临床#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎，疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2022-07-22 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎，疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2022-03-28 liye789132251

    #TBK1#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎，疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-10-17 jj000001

    #Pharm#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎，疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2022-04-14 839640778

    #I期临床试验#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jan 13 00:12:40 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852738, encodeId=93c91852e387a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 22 19:12:40 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024051, encodeId=2d1b202405194, content=<a href='/topic/show?id=5fa61e182a9' target=_blank style='color:#2F92EE;'>#TBK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17182, encryptionId=5fa61e182a9, topicName=TBK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 28 14:12:40 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787738, encodeId=a6ff1e8773840, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 17 14:12:40 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 14 16:12:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029903, encodeId=6b6610299039b, content=新冠肺炎，疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 26 17:12:40 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-08-26 公卫新人

    新冠肺炎，疫情何时才能消失

    0

相关资讯

辉瑞对12岁以下儿童展开新冠疫苗临床试验

据NEXSTAR、CNBC等外媒报道，美国辉瑞制药公司（Pfizer）近日宣布，已开始对12岁以下儿童展开新冠疫苗临床试验。截至目前，尚未有在儿童及婴儿中使用的新冠疫苗批准上市。

临床试验中日期不完整的填补策略

临床试验中，日期采集很多，如随访点，不良反应记录日期，各个指标记录日期。但是常会出现日期不完整的现象。

Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验

脊髓性肌萎缩症是一种常染色体隐性遗传的神经疾病，临床表现差异较大。根据患者起病年龄和临床病程，由重到轻分为4型。大多数受影响的人表现为一种严重的婴儿型，称为脊髓性肌萎缩症1型。

NEJM: 临床试验主要结局是阴性的，接下来怎么办？

2020年4月29日，国际顶级医学期刊《柳叶刀》在线发表了由国家呼吸疾病临床研究中心等多家单位实施的在中国武汉进行的新冠肺炎（COVID-19）抗病毒药物瑞德西韦全球首个随机、双盲、安慰剂对照、多中心

JAHA：不能参加强化降压临床试验个体的人群特征

强化血压治疗试验并不能代表许多心血管风险较低的年轻成年人和当前推荐更低目标血压的伴有多种合并症老年人。

ANANDA Scientific和纽约大学格罗斯曼医学院宣布，评估Liquid Structure™大麻二酚(CBD)治疗创伤后应激障碍(PTSD)的临床试验的首例患者已入组

生物技术制药公司ANANDA和纽约大学格罗斯曼医学院今天宣布，评估在研药物Nantheia™ A1002N5S治疗创伤后应激障碍和PTSD合并创伤性脑损伤患者PTSD症状和神经认知障碍的临床试验已入组

拓展阅读

葛琪兴：解析新冠肺炎特性、传播途径及治疗策略

新型冠状病毒肺炎( 简称新冠肺炎) ，自发生以来造成巨大的社会和经济负担，引起国内外广泛关注。为此，特邀北大荒集团牡丹江医院葛琪兴医师与大家解析新冠肺炎特性、传播途径及治疗策略。

JAMA子刊：新冠肺炎感染是否增加青少年2型糖尿病发病风险？

在10至19岁青少年群体中，COVID-19感染与T2D的发生存在显著关联，尤其在肥胖和住院患者中风险更高。

Hip Pelvis:新冠肺炎疫情对髋部骨折患者康复的影响

大流行疫情对住院护理医院的老年髋部骨折患者术后活动的恢复有不利影响，在完全限制家属进入以防止感染的情况下。

Critical Care Medicine：巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应

我们对重症新冠肺炎住院患者进行的倾向性得分匹配的回顾性观察研究显示，与托珠单抗相比，巴瑞替尼的病死率没有差异，但不良反应显著减少。

Critical Care Medicine：肾素-血管紧张素系统途径疗法与改善新冠肺炎男性住院患者预后相关

男性使用ARB与较低的机械通气和血管活性药物的使用率有关，而在女性中没有观察到该现象。RAS系统失调的性别差异可能导致COVID-19患者预后和对ARB药物反应性的性别差异。

2023年度巨献：中国中药领域十大医学研究出炉

2023年梅斯年终巨献：中国重磅级医学研究成果解读！

关于公开征求ICH《E21：临床试验中纳入妊娠和哺乳期女性》指导原则草案意见的通知

国家药品监督管理局药品审评中心（CDE） · 2025-06-20

SPIRIT-DEFINE 解释和阐述：关于提高早期剂量探索临床试验方案的质量和影响的建议

Equator Network · 2025-06-01

2025 WHO：在临床试验之外紧急使用未经证实的临床干预措施：伦理考虑

世界卫生组织(WHO,The World Health Organization) · 2025-03-25

关于公开征求ICH《E6（R3）：药物临床试验质量管理规范技术指导原则（GCP）》原则及附件1中文翻译稿意见的通知

国家药品监督管理局药品审评中心（CDE） · 2025-03-20

中国临床试验伦理审查指南（英文版）

中国抗癌协会医学伦理学专业委员会 · 2025-02-12

2024 FDA指南：在临床试验中纳入组织活检的注意事项

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2025-01-06